Abzena
Moving medicine forward
Founded 2001 · $75.0M raised
- Founded
- 2001
- Business Model
- B2B
- Website
- abzena.com
- Total Funding
- $75.0M
- Last Round
- $65.0M Growth EquityMar 2022
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Abzena partners with biotechnology and pharmaceutical innovators to advance complex biologic and bioconjugate medicines from discovery through development and manufacturing. Its integrated capabilities include cell line development, bioconjugation, process development, and GMP manufacturing. Scientific teams work across early research, candidate selection, process development, and manufacturing to identify challenges early and reduce development risk.
Summary
Abzena is a Biotech company, founded in 2001. It has raised $75.0M in total across 2 rounds, most recently a $65.0M Growth Equity round in Mar 2022. Investors include Biospring Partners and Welsh, Carson, Anderson & Stowe.
Funding History
Mar 2022
Sign up to see all 2 events
Funding: Growth Equity. Amounts, valuations, and investors where available.
Investors
Similar Companies
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
Therapeutics company working in drug discovery and development using fungi with genomics approach...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Chai Discovery builds frontier AI to predict and reprogram interactions between biochemical molec...
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/abzena"><img src="https://indexed.vc/api/badge/company/abzena" alt="Abzena on Indexed.vc" width="260" height="76" /></a>